scholarly journals Fecal microbiota transplant by push enteroscopy to treat diarrhea caused by Clostridium difficile

2015 ◽  
Vol 13 (2) ◽  
pp. 338-339 ◽  
Author(s):  
Arnaldo José Ganc ◽  
Ricardo Leite Ganc ◽  
Sílvia Mansur Reimão ◽  
Alberto Frisoli Junior ◽  
Jacyr Pasternak
Keyword(s):  
Urinary Tract Infection ◽  
Urinary Tract ◽  
Clostridium Difficile ◽  
Pseudomembranous Colitis ◽  
Fecal Microbiota Transplantation ◽  
Fecal Microbiota ◽  
Push Enteroscopy ◽  
Fecal Microbiota Transplant ◽  
Recommended Treatment

ABSTRACT Clostridium difficile is the major etiological agent of pseudomembranous colitis and is found in up to 20% of adult inpatients. The recommended treatment is antibiotic therapy with metronidazole and/or vancomycin. However, the recurrence rate may reach up to 25% and it increases in each episode. The newest alternative to treat diarrhea due to recurrent Clostridium difficile is fecal microbiota transplantation. The procedure was performed in 12 patients, with a 6-month follow-up on 10 of them. Of the ten cases, bacterial recurrence was diagnosed in only one patient, after a course of antibiotic to treat urinary tract infection, without presenting with diarrhea. The particularity of our study, besides being an unprecedented event in South America, is the way to perform the infusion of fecal microbiota by enteroscopy.

scholarly journals A Systematic Review of the Efficacy and Safety of Fecal Microbiota Transplant for Clostridium difficile Infection in Immunocompromised Patients

2018 ◽  
Vol 2018 ◽  
pp. 1-10 ◽  
Author(s):  
Oluwaseun Shogbesan ◽  
Dilli Ram Poudel ◽  
Samjeris Victor ◽  
Asad Jehangir ◽  
Opeyemi Fadahunsi ◽  
...  
Keyword(s):  
Clostridium Difficile ◽  
English Language ◽  
Fecal Microbiota Transplantation ◽  
Secondary Infection ◽  
Organ Transplant ◽  
Fecal Microbiota ◽  
Immunocompromised Patients ◽  
Serious Adverse Events ◽  
Fecal Microbiota Transplant ◽  
Immunosuppressant Medications

Background. Fecal microbiota transplantation (FMT) has been shown to be effective in recurrent Clostridium difficile (CD) infection, with resolution in 80% to 90% of patients. However, immunosuppressed patients were often excluded from FMT trials, so safety and efficacy in this population are unknown. Methods. We searched MEDLINE and EMBASE for English language articles published on FMT for treatment of CD infection in immunocompromised patients (including patients on immunosuppressant medications, patients with human immunodeficiency virus (HIV), inherited or primary immunodeficiency syndromes, cancer undergoing chemotherapy, or organ transplant, including-bone marrow transplant) of all ages. We excluded inflammatory bowel disease patients that were not on immunosuppressant medications. Resolution and adverse event rates (including secondary infection, rehospitalization, and death) were calculated. Results. Forty-four studies were included, none of which were randomized designs. A total of 303 immunocompromised patients were studied. Mean patient age was 57.3 years. Immunosuppressant medication use was the reason for the immunocompromised state in the majority (77.2%), and 19.2% had greater than one immunocompromising condition. Seventy-six percent were given FMT via colonoscopy. Of the 234 patients with reported follow-up outcomes, 207/234 (87%) reported resolution after first treatment, with 93% noting success after multiple treatments. There were 2 reported deaths, 2 colectomies, 5 treatment-related infections, and 10 subsequent hospitalizations. Conclusion. We found evidence that supports the use of FMT for treatment of CD infection in immunocompromised patients, with similar rates of serious adverse events to immunocompetent patients.

scholarly journals Fecal Microbiota Transplantation for the Treatment of Refractory Recurrent Urinary Tract Infection

2020 ◽  
Vol 136 (4) ◽  
pp. 771-773
Author(s):  
Sarah E. S. Jeney ◽  
Felicia Lane ◽  
Andrew Oliver ◽  
Katrine Whiteson ◽  
Sonia Dutta
Keyword(s):  
Urinary Tract Infection ◽  
Urinary Tract ◽  
Tract Infection ◽  
Recurrent Urinary Tract Infection ◽  
Fecal Microbiota Transplantation ◽  
Fecal Microbiota

scholarly journals Fecal Microbiota Transplantation and Urinary Tract Infection: An Interesting Approach

2017 ◽  
Vol 66 (3) ◽  
pp. 483-483 ◽  
Author(s):  
Benjamin Davido ◽  
Aurélien Dinh ◽  
Laurene Deconinck ◽  
Pierre de Truchis
Keyword(s):  
Urinary Tract Infection ◽  
Urinary Tract ◽  
Tract Infection ◽  
Fecal Microbiota Transplantation ◽  
Fecal Microbiota ◽  
Interesting Approach

Trimethoprim/Sulfamethoxazole-Associated Pseudomembranous Colitis

1982 ◽  
Vol 16 (3) ◽  
pp. 244-247 ◽  
Author(s):  
Steven A. Scott
Keyword(s):  
Urinary Tract Infection ◽  
Adverse Reaction ◽  
Urinary Tract ◽  
Clostridium Difficile ◽  
Tract Infection ◽  
Pseudomembranous Colitis ◽  
Causative Organism ◽  
Oral Vancomycin ◽  
Stool Cultures

A case of TMP/SMX-associated pseudomembranous colitis is described in a patient being treated for a urinary tract infection. Pseudomembranes are visualized on proctosigmoidoscopy, and stool cultures identified Clostridium difficile as the causative organism. The patient was treated successfully with oral vancomycin. A review of this infrequently reported adverse reaction to TMP/SMX is presented, emphasizing etiology and treatment.

Sign in / Sign up

Export Citation Format

Share Document